Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.5 - $1.17 $2,500 - $5,850
5,000 Added 84.75%
10,900 $5,000
Q1 2024

May 15, 2024

BUY
$0.48 - $1.13 $2,304 - $5,423
4,800 Added 436.36%
5,900 $6,000
Q4 2023

Feb 14, 2024

SELL
$0.44 - $1.04 $132 - $312
-300 Reduced 21.43%
1,100 $0
Q3 2023

Nov 14, 2023

SELL
$1.03 - $1.58 $1,442 - $2,212
-1,400 Reduced 50.0%
1,400 $1,000
Q2 2023

Aug 14, 2023

BUY
$0.89 - $2.13 $1,958 - $4,686
2,200 Added 366.67%
2,800 $3,000
Q1 2023

May 15, 2023

SELL
$1.38 - $2.29 $29,173 - $48,410
-21,140 Reduced 97.24%
600 $0
Q4 2022

Feb 14, 2023

SELL
$1.26 - $4.38 $56,322 - $195,786
-44,700 Reduced 67.28%
21,740 $31,000
Q3 2022

Nov 14, 2022

SELL
$3.32 - $5.69 $65,404 - $112,093
-19,700 Reduced 22.87%
66,440 $284,000

Others Institutions Holding VIRX

About Viracta Therapeutics, Inc.


  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $5.63M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.